Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344)

Pohl-Rescigno E, Hauke J, Rhiem K, Moebus V, Furlanetto J, Denkert C, Fasching P, Hanusch C, Tesch H, Weber-Lassalle N, Mueller V, Untch M, Luebbe K, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Loibl S, Schneeweiss A, Hahnen E (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 7-8

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Philipps-Universität Marburg DE Germany (DE) Rotkreuzklinikum München DE Germany (DE) DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH)) DE Germany (DE) GBG Forschungs GmbH (German Breast Group) DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE) Universität zu Köln DE Germany (DE) HELIOS Kliniken DE Germany (DE) Sana Klinikum Offenbach DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE)

How to cite

APA:

Pohl-Rescigno, E., Hauke, J., Rhiem, K., Moebus, V., Furlanetto, J., Denkert, C.,... Hahnen, E. (2020). Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344). In ONCOLOGY RESEARCH AND TREATMENT (pp. 7-8). BASEL: KARGER.

MLA:

Pohl-Rescigno, Esther, et al. "Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 7-8.

BibTeX: Download